JB
JBPHF.US Jacobio Pharmaceuticals Group Co. Ltd.
- Market cap
- USD 591M
- P/E
- 8.4x
- P/B
- 2.92x
- ROE
- -18.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is JBPHF.US undervalued?
Graham numberJBPHF.US trades 4.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Jacobio Pharmaceuticals Group Co. Ltd. fundamental analysis
No fundamental analysis for Jacobio Pharmaceuticals Group Co. Ltd. yet.
Jacobio Pharmaceuticals Group Co. Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Jacobio Pharmaceuticals Group Co. Ltd.
Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies in the People's Republic of China. The company develops sitneprotafib (JAB-3312), an oral allosteric SHP2 inhibitor that is in a Phase III trial for non-small cell lung cancer (NSCLC); glecirasib (JAB-21822), a KRAS G12C allosteric inhibitor in Phase II trials for NSCLC, multi-tumor basket, and colorectal cancer; JAB-8263, a BET inhi…
Full company profileJacobio Pharmaceuticals Group Co. Ltd. financial statements
Jacobio Pharmaceuticals Group Co. Ltd. annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 0.00 | 486M | 153M | 95.7M | 63.5M | 156M | 53.5M |
| Gross Profit | - | 442M | 12.8M | 12.6M | 3.20M | 156M | 52.9M |
| Operating Income | -200M | 209M | -302M | -474M | -408M | -203M | -166M |
| EBITDA | -411M | -1.50B | -290M | -356M | -326M | -121M | -110M |
| Net Income | -425M | -1.51B | -301M | -372M | -359M | -156M | -146M |
| EPS | -0.56 | -1.99 | -0.39 | -0.48 | -0.45 | -0.20 | -0.19 |
| Balance Sheet | |||||||
| Total Assets | 363M | 1.87B | 1.72B | 1.57B | 1.46B | 1.36B | 1.30B |
| Total Liabilities | 833M | 81.2M | 84.7M | 292M | 387M | 436M | 534M |
| Shareholders' Equity | -470M | 1.79B | 1.64B | 1.28B | 1.07B | 923M | 771M |
| Cash & Short-term Investments | 314M | 1.63B | 1.53B | 1.28B | 1.14B | 1.17B | 944M |
| Cash Flow | |||||||
| Operating Cash Flow | -113M | 78.8M | -147M | -292M | -364M | -74.1M | -211M |
| Capital Expenditure | 3.34M | 10.1M | 10.1M | 16.4M | 38.7M | 12.1M | 1.67M |
| Free Cash Flow | -116M | 67.9M | -159M | -309M | -403M | -86.2M | -213M |
| Ratios | |||||||
| ROE | - | -84.7% | -18.4% | -29.0% | -33.5% | -16.9% | -18.9% |
| ROA | -116.9% | -81.1% | -17.5% | -23.6% | -24.6% | -11.5% | -11.2% |
| Net Profit Margin | - | -311.3% | -197.1% | -388.4% | -565.4% | -100.0% | -272.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Jacobio Pharmaceuticals Group Co. Ltd. dividends
Jacobio Pharmaceuticals Group Co. Ltd. has not paid dividends in the last 7 fiscal years.
Who owns Jacobio Pharmaceuticals Group Co. Ltd.
- Insiders 35.75%
- Institutions 9.07%
- Public & others 55.18%
- Shares outstanding 782M
- Free float 409M
Jacobio Pharmaceuticals Group Co. Ltd. company profile
- Company name
- Jacobio Pharmaceuticals Group Co. Ltd.
- Ticker
- JBPHF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 207
- Fiscal year end
- December
- Address
- Building 8, Beijing, China
- Phone
- 86 10 5631 5043
- Website
- jacobiopharma.com
About Jacobio Pharmaceuticals Group Co. Ltd.
Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies in the People's Republic of China. The company develops sitneprotafib (JAB-3312), an oral allosteric SHP2 inhibitor that is in a Phase III trial for non-small cell lung cancer (NSCLC); glecirasib (JAB-21822), a KRAS G12C allosteric inhibitor in Phase II trials for NSCLC, multi-tumor basket, and colorectal cancer; JAB-8263, a BET inhibitor that is in a Phase IIa trial for solid tumors and hematologic malignancies; JAB-BX102, a humanized monoclonal antibody against CD73, which is in a Phase I/IIa trial; JAB-2485, a highly selective Aurora Kinase A (AURKA) inhibitor that is in a Phase I/IIa trial for solid tumors; JAB-23E73, an oral small-molecule pan-KRAS inhibitor that is in a Phase I trial for KRAS-mutant PDAC, CRC, NSCLC, and solid tumors; and JAB-30355, a bioavailable small molecule p53 reactivator that is in a Phase I trial for the treatment of patients with locally advanced or metastatic solid tumors. It is also developing IND-enabling candidates, including JAB-BX467, JAB-BX600, and JAB-BX700 for solid tumor indications. The company has a collaboration agreement with AstraZeneca AB to develop and commercialize JAB-23E73. Jacobio Pharmaceuticals Group Co., Ltd. was founded in 2015 and is headquartered in Beijing, China.
Jacobio Pharmaceuticals Group Co. Ltd. management
10- Dr. Yinxiang WangFounder, Co-CEO & Executive Chairman · born 1965
- Ms. Yunyan HuExecutive Director · born 1962
- Dr. Andrea Wang-Gillam M.D., Ph.D.Co-CEO, Executive VP, Chief Medical Officer and Global Head of R&D · born 1971
- Ms. Tao YangVice President of Human Resources
- Ms. Yanping WangExecutive Vice President of Preclinical R&D
- Dr. Haijun WangSenior Vice President of Information & Data Management, Bioinformatics & Biostatistics
- Ms. Yuli DingExecutive Vice President of Clinical Development
- Dr. LI Amin Ph.D.Senior Vice President of Chemistry
- Ms. Isabella PanGlobal Head of Business Development
- Ms. Qing XueJoint Company Secretary · born 1989